Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Surgical resection has been considered the optimal treatment approach, but only a small proportion of patients are suitable candidates for surgery, and the relapse rate is high. Approaches to prevent recurrence, including chemoembolization before and adjuvant therapy after surgery, have proven to have a limited benefit; liver transplantation is successful in treating limited-stage HCC because only a minority of patients qualify for transplantation. Therefore, new therapeutic strategies are urgently needed. Because in addition to the classical genetic mechanisms of deletion or inactivating point mutations, epigenetic alterations, such as hyperacetylation of the chromatin-associated histones (responsible for gene silencing), are believed to be involved in the development and progression of HCC, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In particular, pre-clinical results obtained using HA-But, an HDAC inhibitor in which butyric acid residues are esterified to a hyaluronic acid backbone and characterized by a high affinity for the membrane receptor CD44, indicated that this class of compounds may represent a promising approach for hepatocellular carcinoma treatment.
Similar content being viewed by others
Article PDF
Abbreviations
- HCC:
-
hepatocellular carcinoma
- HBV:
-
hepatitis B virus
- HCV:
-
hepatitis C virus
- HAT:
-
histone acetyltransferase
- HDAC:
-
histone deacetylase
- NB:
-
sodium butyrate
- TSA:
-
trichostatin A
- SAHA:
-
suberoylanilide hydroxamic acid
- PBA:
-
phenylbutyrate
- HA-But:
-
hyaluronic butyric ester
- HA:
-
hyaluronic acid
References
Parkin DM, Pisani P, Ferlay J . Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827–41.
Yu MC, Yuan JM, Govindarajan S, Ross RK . Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000; 14: 703–9.
Tang ZY . Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445–54.
Parkin DM, Bray FI, Devesa SS . Cancer burden in the year 2000: The global picture. Eur J Cancer 2001; 37: S4–66.
Deuffic S, Poynard T, Buffat L, Valleron AJ . Trends in primary liver cancer. Lancet 1998; 351: 214–5.
El-Serag HB, Devila JA, Petersen NJ, McGlynn KA . The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817–23.
Thorgeisson SS, Grisham JW . Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339–46.
Ding X, Park YN, Taltavull TC, Thung SN, Jin XM, Jin Y, et al. Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: a comparison among six different countries. Jpn J Infect Dis 2003; 56: 12–8.
National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. Hepatology 2002; 36: S1–20.
Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83: 1219–22.
Figueras J, Jaurrieta E, Vails C, Ramos E . Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000; 190: 580–7.
Lai EC, Lo CM, Fan ST, Liu CL, Wong J . Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133: 183–8.
Yamamoto M, Arii S, Sugahara K, Tobe T . Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996; 83: 336–40.
Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001; 78: 110–5.
Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 2002; 224: 109–14.
Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J . Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353–7.
CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 1998; 352: 17–20.
Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON . Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998; 42: 442–7.
Pignata S, Daniele B, Gallo C, De Vivo R, Monfardini S, Perrone F . Endocrine treatment of hepatocellular carcinoma: Any evidence of benefit? Eur J Cancer 1998; 34: 25–32.
Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 50–70.
Ozturk M . Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999; 19: 235–42.
Moradpour D, Wands JR . Molecular pathogenesis of hepatocellular carcinoma. In: Zakim D, Boyer TD, ( eds), Hepatology. A Textbook of liver disease. Philadelphia: WB Sauders; 2002. p 1333–54.
Suriawinata A, Xu R . An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004; 24: 77–88.
Matsuo M, Sakurai H, Saiki I . ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using hepatocellular carcinoma model. Mol Cancer Ther 2003; 2: 557–61.
Midgley R, Kerr D . Bevacizumab: current status and future directions. Ann Oncol 2005; 16: 999–1004.
Sebti SM, Adjei AA . Farnesyltransferase inhibitors. Semin Oncol 2004; 31: 28–39.
Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 389–94.
Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, et al. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 2002; 25: 224–6.
Alleghi R, Dissoni P, Barni S, Ardizzola A, Tanchini G, Piperno A, et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994; 30A: 167–70.
Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371–81.
Sangro B, Herraiz M, Prieto J . Gene therapy of neoplastic liver diseases. Int J Biochem Cell Biol 2003; 35: 135–48.
Anderson SC, Johnson DE, Harris MP, Engler H, Hancock W, Huang WM, et al. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 1998; 4: 1649–59.
Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, et al. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther 2003; 10: 840–9.
Bilbao R, Gerolami R, Bralet MP, Qian C, Tran PL, Tennant B, et al. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther 2000; 7: 657–62.
Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin 12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389–97.
Schmitz V, Wang L, Barajas M, Peng D, Prieto J, Qian C . A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen. Gene Ther 2002; 9: 1600–6.
Kondoh N, Wakatsuki T, Hada A, Shuda M, Tanaka K, Arai M, et al. Genetic and epigenetic events in human hepatocarcinogenesis. Int J Oncol 2001; 18: 1271–8.
Jenuwein T, Allis CD . Translating the histone code. Science 2001; 293: 1074–80.
Grunstein M . Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349–52.
Wade PA, Pruss D, Wolffe AP . Histone acetylation: chromatin in action. Trends Biochem Sci 1997; 22: 128–32.
Hebbes TR, Thome AW, Crane-Robinson C . A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J 1988; 7: 1395–402.
de Ruijter Aj, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB . Histone deacetylases: characterisation of the classical HDAC family. Biochem J 2003; 3707: 37–49.
Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D . Functional significance of histone deacetylase diversity. Curr Opin Genet 2001; 11: 162–6.
Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelley WK . Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194–202.
Csordas A . The biological role of histone acetylation. Biochemistry 1990; 332: 353–7.
Marks PA, Richon VM, Breslow R, Rifkind RA . Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477–83.
Vidali G, Boffa LC, Bradbury EM, Allfrey VG . Butyrate suppression of histone deacetylation leads to accumulation of multi-acetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA 1978; 75: 2239–43.
McIntyre A, Gibson PR, Young GP . Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 1993; 34: 386–91.
Yoshida M, Kijima M, Akita M, Beppu T . Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174–9.
Richon VM, Zhou X, Rifkind RA, Marks PA . Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001; 27: 260–4.
Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T . Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993; 268: 22 429–35.
Nakajima H, Kim YB, Erano H, Yoshida M, Horinouchi S . FR901228 a potent antitumor antibiotic is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126–33.
Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 1996; 93: 13143–7.
Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al. A synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592–7.
Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969–78.
Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S . Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999; 18: 2461–70.
Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Long W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid (SAHA) administered intravenously. Clin Cancer Res 2003; 9: 3578–88.
Vigushin DM . FR-901228 Fujisawa/National Cancer Institute. Curr Opin Investig Drugs 2002; 3: 1396–402.
Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959–67.
Gojo I, Karp JE, Mann D . Phase I study of histone deacetylase inhibitor (HDI)MS-275 in adults with refractory or relapsed haematologic malignancies. Proc Am Soc Hem 2002; abstract no 2198.
Miller AA, Kurschel E, Osieka R, Schmidt CG . Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987; 23: 1283–7.
Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Stucchi L, et al. Hyaluronic acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest New Drugs 2004; 22: 207–17.
Tammi MI, Day AJ, Turley EA . Hyaluronan and homeostasis: a balancing act. J Biol Chem 2001; 277: 4581–4.
Eraser JR, Alcorn D, Laurent TC, Robinson AD, Ryan GB . Uptake of circulating hyaluronic acid by the rat liver. Cell Tissue Res 1985; 242: 505–10.
Isacke CM, Yarwood H . The hyaluronan receptor CD44. J Biochem Cell Biol 2002; 34: 718–21.
Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443–55.
Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13–24.
Lara-Pezzi E, Serrador JM, Montoya MC, Zamora D, Yanez-Mo M, Carretero M, et al. The hepatitis B virus protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology 2001; 33: 1270–81.
Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective in vitro activity against human B-cell chronic lymphocytic leukaemia cells. Blood 1999; 94: 1401–8.
Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 2004; 10: 4822–30.
Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 3107–10.
Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36: 233–40.
Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekstrom TJ . Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 2003; 22: 579–88.
Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, et al. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 2004; 41: 436–45.
Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697–702.
Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001; 98: 15089–94.
Tannapfel A, Wittekind C . Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch 2002; 440: 345–52.
McGary CT, Yannariello-Brown J, Kim DW, Stinson TC, Weigel PH . Degradation and intracellular accumulation of a residualizing hyaluronan derivative by liver endothelial cells. Hepatology 1993; 18: 1465–76.
Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13: 1929–39.
Delpuech O, Trabut JB, Carnot F, Feuillard J, Brechot C, Kremsdorf D . Identification, using cDNA microarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene 2002; 21: 2926–37.
Gustafsson S, Bjorknan T, Westlin JE . Labelling of high molecular weight hyaluronan with 125-I-tyrosine. Studies in vitro and in vivo in the rat. Glyco Conj J 1994; 11: 608–13.
Saegusa S, Shuji I, Kawarada Y . Changes in serum hyaluronic acid levels and expression of CD44 and CD44 mRNA in hepatic sinusoidal endothelial hepatectomy in cirrhotic rats. World J Surg 2002; 26: 694–9.
Barbara-Guillem E, Alonso-Varona A, Vidal-Vanaclocha F . Selective implantation and growth in rats and mice of experimental liver metastasis in acinar zone one. Cancer Res 1989; 49: 4003–10.
Carrascal MT, Mendoza L, Valcarcel M, Salado C, Egilegor E . Interleukin-18 binding protein reduces B16 melanoma hepatic metastasis in neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003; 63: 491–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Coradini, D., Speranza, A. Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin 26, 1025–1033 (2005). https://doi.org/10.1111/j.1745-7254.2005.00195.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00195.x
Keywords
This article is cited by
-
Replication of a chronic hepatitis B virus genotype F1b construct
Archives of Virology (2016)
-
Histone acetyltransferase PCAF Up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling
Molecular Cancer (2013)
-
Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
Journal of Translational Medicine (2011)
-
Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment
Apoptosis (2011)
-
Short Chain Saturated Fatty Acids Decrease Circulating Cholesterol and Increase Tissue PUFA Content in the Rat
Lipids (2010)